Ireland Pharmaceuticals and Healthcare Report Q2 2016

76 pages report Published in
Pharmaceuticals
Publisher: Business Monitor International

arrowFor This Report

BMI View: Ireland’s pharmaceutical and healthcare sector will continue to observe strong development
over a multi-quarter horizon. This outlook is reflected in ongoing solid levels of investment and job creation
in both the pharmaceutical and healthcare industries. While pharmaceutical exports will continue to be
supported by Ireland’s main export markets growth, including the US, the UK and Western Europe, the
domestic Irish market, albeit small in regional terms, will gradually recover and return to growth on the
back of economic expansion, rising consumption and government’s fiscal loosening over the forecast
period.
Headline Expenditure Projections
? Pharmaceuticals: EUR2.32bn (USD2.55bn) in 2015 to EUR2.27bn (USD2.43bn) in 2016; -2.2% in
local currency terms and -4.8% in US dollar terms. Forecast revised slightly downwards from last
quarter.
? Healthcare: EUR14.87bn (USD16.35bn) in 2015 to EUR15.08bn (USD16.14bn) in 2016; 1.5% in local
currency terms and -1.3% in US dollar terms. Forecast in line with last quarter.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Ireland 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Ireland 2012-2020) 14
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Ireland 2012-2020) 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Ireland 2012-2020) 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Ireland 2012-2020) 18
Prescription Drug Market Forecast 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Ireland 2012-2020) 21
OTC Medicine Market Forecast 22
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Ireland 2012-2020) 23
Pharmaceutical Trade Forecast 24
Table: Top 15 Pharmaceuticals and Healthcare Export Companies In 2013 26
Table: Pharmaceutical Trade Data And Forecasts (Ireland 2014-2020) 26
Table: Pharmaceutical Trade Data And Forecasts local currency (Ireland 2014-2020) 27
Industry Risk/Reward Index 28
Western Europe Risk/Reward Index 28
Ireland Risk/Reward Index 33
Rewards 33
Risks 34
Regulatory Review 36
Pricing Regime 41
Reimbursement Regime 44
Market Overview 48
Healthcare Sector 49
Table: Health Status 52
Table: Healthcare Funding 52
Table: Healthcare Resources (Ireland 2010-2015) 53
Table: Healthcare Personnel (Ireland 2010-2015) 53
Table: Healthcare Activity (Ireland 2010-2015) 54
Research & Development 54
Clinical Trials 55
Epidemiology 56
Competitive Landscape 59
Research-Based Industry 59
Table: Multinational Market Activity 61
Table: Pharmaceutical Companies In Ireland 62
Generic Drugmakers 63
Pharmaceutical Distribution 64
Demographic Forecast 65
Table: Population Headline Indicators (Ireland 1990-2025) 66
Table: Key Population Ratios (Ireland 1990-2025) 66
Table: Urban/Rural Population & Life Expectancy (Ireland 1990-2025) 67
Table: Population By Age Group (Ireland 1990-2025) 67
Table: Population By Age Group % (Ireland 1990-2025) 68
Glossary 70
Methodology 72
Pharmaceutical Expenditure Forecast Model 72
Healthcare Expenditure Forecast Model 72
Notes On Methodology 73
Risk/Reward Index Methodology 74
Index Overview 75
Table: Pharmaceutical Risk/Reward Index Indicators 75
Indicator Weightings 76

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Ireland 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Ireland 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Ireland 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Ireland 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Ireland 2012-2020)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Ireland 2012-2020)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Ireland 2012-2020)
Table: Top 15 Pharmaceuticals and Healthcare Export Companies In 2013
Table: Pharmaceutical Trade Data And Forecasts (Ireland 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (Ireland 2014-2020)
Table: Health Status
Table: Healthcare Funding
Table: Healthcare Resources (Ireland 2010-2015)
Table: Healthcare Personnel (Ireland 2010-2015)
Table: Healthcare Activity (Ireland 2010-2015)
Table: Multinational Market Activity
Table: Pharmaceutical Companies In Ireland
Table: Population Headline Indicators (Ireland 1990-2025)
Table: Key Population Ratios (Ireland 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Ireland 1990-2025)
Table: Population By Age Group (Ireland 1990-2025)
Table: Population By Age Group % (Ireland 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators

Related Reports

  • Ireland Pharmaceuticals and Healthcare Report Q3 2014BMI View: We anticipate further cuts to healthcare spending to come in the coming months, in the wake of an EU Commission report citing public healthcare expenditure in Ireland as one of the highest in Europe. This will have a knock-on effect on government pharmaceutical expenditure, and means that companies operating in the country will face ongoing revenue-restricting measures. Meanwhile, we believe the worst of the pharmaceutical patent cliff is over, as the sector profits […]
  • Ireland Pharmaceuticals and Healthcare Report Q4 2014BMI View: The US government and the OECD recent proposals to discourage corporate inversion pose downside risk to the rate of M&A deals that opt to establish their new headquarters' domicile in Ireland, although the megatrend of consolidation within the pharmaceutical industry, including cross-border mergers and redomiciling in Ireland for tax saving purposes, is expected to continue over the near term. More broadly, due to potential acquisitive interest in different Irish […]
  • Ireland Pharmaceuticals and Healthcare Report Q1 2016BMI View: In line with our long-standing view, manufacturing investment in Ireland's pharmaceutical sector remained strong in H215, and we expect this trend to continue over a multi-quarter horizon. Sustained expansion of Ireland's economy will be underpinned by an increasingly robust consumer spending story, as well as accelerating export demand, which are set to benefit pharmaceutical production indices and overall healthcare sector growth. However, despite a recent increase in […]
  • Ireland Pharmaceuticals and Healthcare Report Q3 2015BMI View: In line with our long-standing view, merger and acquisition activity targeting Irish pharmaceutical firms has remained intense in H115, while this trend is expected to continue over a multiquarter horizon against a backdrop of strong fundamentals and Ireland's government policies to attract foreign investment in the pharmaceutical sector. Recent acquisitive trends are illustrated by ongoing merger bids between Mylan, Perrigo and Teva, as well as Actavis' acquisition of […]
  • Ireland Pharmaceuticals and Healthcare Report Q2 2015BMI View: Merger and acquisition activity targeting Irish pharmaceutical companies will remain strong due to long-term fundamentals, including promising drug pipelines, investment and innovation incentives and higher productivity by existing levels of industry agglomeration. The increased international regulatory scrutiny of corporate tax regimes poses downside risks to certain corporate inversion deals, although this should not affect substantially the broader Irish […]